Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gebra Cuyun Carter
Outcomes in Patients With Aggressive or Refractory Disease From REVEL, a Randomized Phase III Study of Docetaxel With Ramucirumab or Placebo for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Related publications
A Randomized, Double-Blind, Phase II Study of Ramucirumab Plus Docetaxel vs Placebo Plus Docetaxel in Japanese Patients With Stage IV Non-Small Cell Lung Cancer After Disease Progression on Platinum-Based Therapy
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
A Phase II Trial of Docetaxel and Ifosfamide for Patients With Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting
Cancer Research and Treatment
Cancer Research
Oncology
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Korean Journal of Internal Medicine
Internal Medicine
Phase II Study of Ramucirumab and Docetaxel for Previously Treated Non-Small Cell Lung Cancer Patients With Malignant Pleural Effusion: Protocol of PLEURAM Study
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase III Study of Cisplatin With Pemtrexed or Vinorelbine Plus Concurrent Late Course Accelerated Hyperfractionated Radiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Oncotarget
Oncology
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Lipegfilgrastim in Patients With Non-Small Cell Lung Cancer Receiving Myelosuppressive Therapy
SpringerPlus
Multidisciplinary
Phase I Trial of Sorafenib in Combination With Gefitinib in Patients With Refractory or Recurrent Non Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer
Journal of Cancer
Oncology
